Chargement en cours...
Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
OBJECTIVES: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. RESULTS: A total of 6 randomized...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669972/ https://ncbi.nlm.nih.gov/pubmed/29137346 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18312 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|